Researchers reported on a study that assessed the clinical utility of minimal residual disease (MRD) monitoring in elderly patients with multiple myeloma (MM) included in the PETHEMA/GEM2010MAS65 trial.
Beth Faiman expresses her excitement about the newly approved multiple myeloma treatments but believes that they will also bring about new challenges.
R. Donald Harvey believes that developing well-tolerated drugs is the key to improving the standard of care in managing patients with hematologic malignancies.
Bortezomib/Thalidomide/Dexamethasone (VTD) Is Superior to Bortezomib/Cyclophosphamide/ Dexamethasone (VCD) Prior to ASCT for Patients with De Novo MM
Researchers presented results of the randomized, prospective IFM 2013-04 trial that compared the induction treatment regimens of bortezomib/thalidomide/dexamethasone and bortezomib/cyclophosphamide/dexamethasone prior to autologous stem-cell transplant (ASCT) in patients with de novo multiple myeloma (MM).
Researchers reported results of in-depth molecular profiling performed on samples from African Americans and European Americans with multiple myeloma enrolled in the longitudinal CoMMpass study.
Factors Influencing Second-Line Treatment with Triplet Therapy for Patients with RRMM in Routine Care
This study assessed factors that influenced the use of 3-drug combination therapy as a second-line treatment choice in patients with relapsed/refractory multiple myeloma (RRMM) who were managed in routine care.
In this study, the clinical value of minimal residual disease (MRD) status in achieving prolonged remissions was assessed in patients with multiple myeloma (MM) who had achieved at least very good partial response or complete response at 4 to 8 months and 12 to 24 months, or long-term relapse-free survivors (>6 years).
A randomized phase 2 study evaluated the safety and antimyeloma activity of 2 different doses of ixazomib (4 mg or 5.5 mg weekly for 3 weeks with a week off) plus dexamethasone (40 mg weekly) in patients with relapsed multiple myeloma (MM) but who were not refractory to bortezomib; results of this study were reported at the meeting.
Researchers presented updated results of the randomized phase 3 ELOQUENT-2 study that evaluated the anti-SLAM7 monoclonal antibody elotuzumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM).
Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study.
Page 16 of 19
Results 151 - 160 of 184
Results 151 - 160 of 184